GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics, particularly through its innovative blood tests designed for multi-cancer early detection (MCED). Utilizing proprietary genomic technologies, the company is committed to enhancing precision medicine by offering vital insights for proactive health management and improving patient outcomes. GRAIL is poised to address critical gaps in cancer screening and diagnostics, establishing itself as a pivotal entity in the dynamic oncology landscape, with the potential to significantly impact the future of cancer care.
| Revenue (TTM) | $165.26M |
| Gross Profit (TTM) | $82.15M |
| EBITDA | $-378.49M |
| Operating Margin | -332.00% |
| Return on Equity | -16.10% |
| Return on Assets | -12.00% |
| Revenue/Share (TTM) | $4.11 |
| Book Value | $56.93 |
| Price-to-Book | 1.19 |
| Price-to-Sales (TTM) | 18.91 |
| EV/Revenue | 13.68 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 25.70% |
| Shares Outstanding | $44.67M |
| Float | $34.29M |
| % Insiders | 5.02% |
| % Institutions | 86.89% |
Volatility is currently expanding
GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices.
GRAIL faces a binary FDA approval event for Galleri, with significant stock movement expected based on the outcome. Despite disappointing NHS-Galleri trial results, I believe the true value of the test would have been apparent with a longer monitoring period. While GRAL has a solid cash position, commercialization delays could see the company having to raise a large amount of capital on unfavorable terms.
Grail said on Friday the U.S. FDA plans to hold a meeting of outside experts to review its multi-cancer screening test Galleri in September, sending its shares up 4% in morning trade.
MENLO PARK, Calif., Aug. 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept.
GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript
Q2 Galleri ® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to $42.6 Million Galleri Test Volume and Revenue are up 42% and 30% Year-Over-Year, Respectively, for the First Half of the Year NHS-Galleri and PATHFINDER 2 Study Results Presented at 2026 ASCO Annual Meeting Demonstrated Consistent Strong Performance and Clinical Utility for Galleri Completed $110 Million Equity Financing With Samsung MENLO PARK, Calif., Aug. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter of 2026.
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against GRAIL, Inc. (“Grail” or the “Company”) (NASDAQ: GRAL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GRAIL, Inc. (NASDAQ: GRAL). Shareholders who purchased shares of GRAL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
LOS ANGELES, Aug. 04, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Grail, Inc., (“Grail” or the "Company") (NASDAQ: GRAL) investors of a class action on behalf of investors that bought securities between May 13, 2025 and February 19, 2026, inclusive (the “Class Period”). Grail investors have until August 4, 2026 to file a lead plaintiff motion.
SAN FRANCISCO, Aug. 4, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in GRAIL, Inc. (NASDAQ: GRAL) that a securities fraud class action lawsuit has been filed, and the firm is actively urging investors with substantial losses to submit your losses now . The upcoming lead plaintiff deadline is August 4, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GRAL and any ticker you trade — then tracks every position and per-strategy win rate.
